Preparing for commercialization?
Discuss commercial readiness, launch timing and organizational decisions with PharmaKonsult.
PharmaKonsult Framework
PharmaKonsult Commercial Readiness Framework
Seven pillars for evaluating whether an emerging biotechnology company is prepared to commercialize.
What Is the PharmaKonsult Commercial Readiness Framework?
A biotechnology launch readiness assessment evaluates whether the strategy, organization, capabilities and execution plan are sufficiently developed for commercialization. The PharmaKonsult Commercial Readiness Framework organizes that evaluation into seven pillars used across advisory engagements, board discussions and leadership planning.
The framework is designed for emerging biotechnology companies—particularly those preparing for a first U.S. commercial launch across rare disease, neuroscience and specialty markets.
Seven Pillars of Commercial Readiness
1
Market Reality
Diagnosed population, addressable patients, treatment pathways and competitive dynamics—not prevalence alone.
2
Patient Journey
How patients enter care, where diagnosis is delayed, referral networks and points of abandonment.
3
Evidence
Clinical, economic and real-world evidence required for physician confidence and payer decisions.
4
Access
Reimbursement, specialty pharmacy, patient support and the operational path from prescription to initiation.
5
Organization
Capabilities, structure, hiring sequence and what should be internal versus outsourced.
6
Leadership
Commercial judgment, cross-functional influence, board communication and accountability.
7
Execution
Priorities, owners, milestones, dependencies, metrics and launch governance.
How Leadership Should Use the Framework
The framework is not a scorecard for its own sake. It is a shared language for CEOs, boards and commercial leaders to ask:
- What is ready?
- What remains incomplete?
- What could materially affect launch performance if leadership does not address it?
Use it alongside the Biotechnology Commercial Readiness Checklist and the 36-month launch roadmap, and when commissioning a formal launch readiness assessment.
Who It Is For
Biotechnology CEOs, founders, Chief Commercial Officers, boards, investors and leadership teams preparing for commercialization or evaluating commercial risk before major hiring, financing or partnership decisions.
